Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-354 · 1 trial · 1 indication
Hematology, Chemistry, Urinalysis
| Arm | Type | Description |
|---|---|---|
| Group 1, low dose | EXPERIMENTAL | ABT-354 |
| Group 2, high dose | EXPERIMENTAL | ABT-354 |
| Name | Type | Description |
|---|---|---|
| ABT-354 | DRUG | ABT-354 Low Dose |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Meets the National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association criteria for probable Alzheimer's Disease * Has a Mini-Mental State Examination total score of 16 to 26, inclusive, at Screening * Has a Mo...
Top 20 of 24 competitors
ABT-354 is an investigational small molecule being developed for the treatment of Alzheimer's Disease. It is intended for patients with mild-to-moderate Alzheimer's Disease who are on stable doses of acetylcholinesterase inhibitors. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
The molecular target of ABT-354 has not been disclosed. As a small molecule in early clinical development for Alzheimer's Disease, its specific mechanism of action is not publicly available. The drug is being studied for its safety, tolerability, and pharmacokinetics in patients with mild-to-moderate Alzheimer's Disease.
ABT-354 is being developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. AbbVie is conducting clinical research on this investigational drug for Alzheimer's Disease, with the drug currently in Phase 1 development.
ABT-354 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The drug is being studied for safety, tolerability, and pharmacokinetics in patients with mild-to-moderate Alzheimer's Disease, and remains in early-stage clinical testing.
ABT-354 has one completed clinical trial, identified as NCT01908010. This Phase 1 study evaluated the safety, tolerability, and pharmacokinetics of ABT-354 in subjects with mild-to-moderate Alzheimer's Disease on stable doses of acetylcholinesterase inhibitors. The trial enrolled 20 participants in the United States and was double-blind, randomized, and controlled.